BML Inc operates in the Medical laboratories sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BML Inc with three other
pharmaceutical manufacturers in Asia:
Miraca Holdings Incorporated
sales of 204.25 billion Japanese Yen [US$1.81 billion]
of which 65%
was Clinical Examination),
Dr. Lal PathLabs Ltd
(9.12 billion Indian Rupees [US$139.78 million]
of which 100%
was Healthcare), and
Falco Holdings Co Ltd
(45.97 billion Japanese Yen [US$407.30 million]
of which 61%
was Medical Test).
BML Inc reported sales of ¥111.24 billion (US$985.61 million)
March of 2017.
increase of 2.0%
versus 2016, when the company's sales were ¥109.02 billion.
Sales at BML Inc have increased during each of the previous five years
(and since 2012, sales have increased a total of 21%).
Sales of Testing Business saw an increase
2.3% in 2017, from
¥103.57 billion to ¥105.93 billion.
Not all segments of BML Inc experienced an increase in sales in 2017:
sales of Other fell 4.9% to ¥1.43 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).
BML Inc also experienced decreases in sales in
Medical Information Systems Business (down 1.7% to ¥3.88 billion)